Prosecution Insights
Prosecution Insights
21 pending office actions • 13 art units • 21 examiners • 0 of 21 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (5%) |
| §103 only | 3 (14%) |
| §112 only | 3 (14%) |
| Double-patenting only | 3 (14%) |
| Double-patenting + other | 5 (24%) |
| Multi-statute (no §101) | 5 (24%) |
| No statute on record | 1 (5%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BRADLEY, CHRISTINA | 1 | 62.9% | +33.0% |
| PUTTLITZ, KARL J | 1 | 69.1% | +18.5% |
| LUNDE, GRACE HENRY | 1 | 63.0% | +38.9% |
| CHERNYSHEV, OLGA N | 1 | 54.5% | +34.2% |
| OUSPENSKI, ILIA I | 1 | 77.5% | +20.4% |
| BUCCINI, MICHELLE CALLAHAN | 1 | — | — |
| HELLMAN, KRISTINA M | 1 | 65.5% | +55.1% |
| ALSOMAIRY, SARAH ABDOALATIF | 1 | 59.4% | +26.5% |
| XIAO, YAN | 1 | 67.8% | +51.6% |
| BUNNER, BRIDGET E | 1 | 64.4% | +20.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18001637 | DETERGENT AND METHOD FOR PURIFYING A BIOTHERAPEUTIC | SWIFT, CANDICE LEE | 28d overdue |
| 18836305 | GLP-1 AND GLUCAGON DUAL AGONIST PEPTIDES WITH IMPROVED BIOLOGICAL STABILITY | BRADLEY, CHRISTINA | — |
| 18253665 | FUSION PROTEINS COMPRISING AN E2 UBIQUITIN OR UBIQUITIN-LIKE CONJUGATING DOMAIN AND A TARGETING DOMAIN FOR SPECIFIC PROTEIN DEGRADATION | ALSOMAIRY, SARAH ABDOALATIF | — |
| 17755605 | METHODS OF USING IL-33 ANTAGONISTS | MERTZ, PREMA MARIA | — |
| 18559910 | MODIFIED FCRN BINDING FRAGMENTS WITH IMPROVED HALF-LIFE | WEN, SHARON X | — |
| 18178687 | TREATMENT METHODS USING CTLA-4 AND PD-1 BISPECIFIC ANTIBODIES | VAN DRUFF, SYDNEY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18169497 | COMBINATION THERAPIES FOR TREATMENT OF CANCER WITH THERAPEUTIC BINDING MOLECULES | BUNNER, BRIDGET E | 6d |
| 18025883 | A Scoring Method for an Anti-B7H4 Antibody-Drug Conjugate Therapy | XIAO, YAN | 33d |
| 18836305 | GLP-1 AND GLUCAGON DUAL AGONIST PEPTIDES WITH IMPROVED BIOLOGICAL STABILITY | BRADLEY, CHRISTINA | — |
| 18427293 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES AND USES THEREOF | PUTTLITZ, KARL J | — |
| 18566712 | METHODS FOR TREATING ATOPIC DERMATITIS AND RELATED DISORDERS | LUNDE, GRACE HENRY | — |
| 18557480 | METHODS FOR TREATING VASCULAR INFLAMMATION, ATHEROSCLEROSIS AND RELATED DISORDERS | CHERNYSHEV, OLGA N | — |
| 18490856 | ANTI-B7-H1 ANTIBODIES FOR TREATING TUMORS | OUSPENSKI, ILIA I | — |
| 18257756 | POLYPEPTIDES AND USES THEREOF | HELLMAN, KRISTINA M | — |
| Art Unit | Apps |
|---|---|
| 1643 | 3 |
| 1642 | 2 |
| 1675 | 2 |
| 1647 | 2 |
| 1654 | 1 |
| 1646 | 1 |
| 1622 | 1 |
| 1683 | 1 |
| 1674 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18836305 | GLP-1 AND GLUCAGON DUAL AGONIST PEPTIDES WITH IMPROVED BIOLOGICAL STABILITY | BRADLEY, CHRISTINA | — | §101§102§103DP | Non-Final OA | — | Pending | Aug 06, 2024 |
| 18427293 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES AND USES THEREOF | PUTTLITZ, KARL J | 1642 | DP | Non-Final OA | — | Pending | Jan 30, 2024 |
| 18566712 | METHODS FOR TREATING ATOPIC DERMATITIS AND RELATED DISORDERS | LUNDE, GRACE HENRY | — | §103§112DP | Non-Final OA | — | Pending | Dec 04, 2023 |
| 18557480 | METHODS FOR TREATING VASCULAR INFLAMMATION, ATHEROSCLEROSIS AND RELATED DISORDERS | CHERNYSHEV, OLGA N | 1675 | §102§112DP | Non-Final OA | — | Pending | Oct 26, 2023 |
| 18490856 | ANTI-B7-H1 ANTIBODIES FOR TREATING TUMORS | OUSPENSKI, ILIA I | — | DP | Non-Final OA | — | Pending | Oct 20, 2023 |
| 18346884 | IL33 ANTIBODIES AND METHODS OF USING THE SAME | BUCCINI, MICHELLE CALLAHAN | 1675 | §102§112DP | Non-Final OA | — | Pending | Jul 05, 2023 |
| 18257756 | POLYPEPTIDES AND USES THEREOF | HELLMAN, KRISTINA M | 1654 | §112Other | Non-Final OA | — | Pending | Jun 15, 2023 |
| 18253665 | FUSION PROTEINS COMPRISING AN E2 UBIQUITIN OR UBIQUITIN-LIKE CONJUGATING DOMAIN AND A TARGETING DOMAIN FOR SPECIFIC PROTEIN DEGRADATION | ALSOMAIRY, SARAH ABDOALATIF | 1646 | §103§112 | Non-Final OA | — | Pending | May 19, 2023 |
| 18025883 | A Scoring Method for an Anti-B7H4 Antibody-Drug Conjugate Therapy | XIAO, YAN | 1642 | §112 | Final Rejection | 33d | Pending | Mar 11, 2023 |
| 18169497 | COMBINATION THERAPIES FOR TREATMENT OF CANCER WITH THERAPEUTIC BINDING MOLECULES | BUNNER, BRIDGET E | 1647 | Other | Final Rejection | 6d | Pending | Feb 15, 2023 |
| 17962610 | PYRROLOBENZODIAZEPINE ANTIBODY CONJUGATES | ELENISTE, PIERRE PAUL | 1622 | §103Other | Final Rejection | 1d overdue | Pending | Oct 10, 2022 |
| 17906123 | THERAPEUTIC METHODS FOR THE TREATMENT OF SUBJECTS WITH RISK ALELLES IN IL33 | KAPUSHOC, STEPHEN THOMAS | 1683 | §103 | Final Rejection | — | Pending | Sep 12, 2022 |
| 17755605 | METHODS OF USING IL-33 ANTAGONISTS | MERTZ, PREMA MARIA | 1674 | §103§112 | Non-Final OA | — | Pending | May 03, 2022 |
| 18414892 | BCMA Monoclonal Antibody-Drug Conjugate | BRISTOL, LYNN ANNE | 1643 | §112DPOther | Non-Final OA | — | Pending | Jan 17, 2024 |
| 18559910 | MODIFIED FCRN BINDING FRAGMENTS WITH IMPROVED HALF-LIFE | WEN, SHARON X | 1641 | §102§103§112 | Non-Final OA | — | Pending | Nov 09, 2023 |
| 18481725 | COMPOSITIONS AND METHODS OF TREATING CANCER WITH CHIMERIC ANTIGEN RECEPTORS TARGETING CLAUDIN 18.2 | CHATTIN, AMY MARIE | 1643 | §112 | Non-Final OA | — | Pending | Oct 05, 2023 |
| 18360542 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | HAMA, JOANNE | 1647 | §103Other | Non-Final OA | 42d | Pending | Jul 27, 2023 |
| 18001637 | DETERGENT AND METHOD FOR PURIFYING A BIOTHERAPEUTIC | SWIFT, CANDICE LEE | 1657 | §103§112 | Non-Final OA | 28d overdue | Pending | Jul 14, 2023 |
| 18351821 | METHODS FOR EXPANDING T CELL POPULATIONS | CANDELARIA, JULIANA IRENE | 1634 | §103DPOther | Non-Final OA | 60d | Pending | Jul 13, 2023 |
| 18178687 | TREATMENT METHODS USING CTLA-4 AND PD-1 BISPECIFIC ANTIBODIES | VAN DRUFF, SYDNEY | 1643 | §103§112Other | Final Rejection | — | Pending | Mar 06, 2023 |
| 17783463 | Compositions and Methods of Treating Cancer with Chimeric Antigen Receptors Targeting Glypican 3 | VIVLEMORE, TRACY ANN | 1638 | DP | Final Rejection | 3d overdue | Pending | Jun 08, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial